OncLive SOSS

Exploring the Management of Pediatric Relapsed/Refractory Acute Leukemia - Episode 2

Implications of the FDA Approval of Revumenib in KMT2A+ R/R Acute Leukemia

May 22, 2025

Lia Gore, MD, Sarah K. Tasian, MD

Lia Gore, MD, and Sarah K. Tasian, MD, on the significance of the FDA approval of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Current Treatment Strategies in Pediatric R/R AML and ALL

EP. 2: Implications of the FDA Approval of Revumenib in KMT2A+ R/R Acute Leukemia

EP. 3: When to Test for KMT2A Rearrangements and Other Alterations in Pediatric Acute Leukemia

EP. 4: Integrating 25-mg Tablets of Revumenib Into Pediatric R/R Acute Leukemia Management

EP. 5: Breaking Down Treatment Expectations With Revumenib in Pediatric KMT2A+ R/R Acute Leukemia

EP. 6: Factors to Consider in Pediatric Acute Leukemia Management

EP. 7: Treatment Trends and Ongoing Research in Pediatric Acute Leukemia

x